DiaCarta, Inc., Awarded $2 Million NCI Contract to Pursue Regulatory Approval of Innovative Cancer Radiation Response Blood Test
DIACARTA, Inc., a precision diagnostic company and leading developer of products for nucleic acid-based detection assays, announced today that it has received a $2 million National Cancer Institute (NCI) Small Business Innovation Research (SBIR) contract to continue development of its RadTox™ cfDNA radiation therapy toxicity monitoring test kit for cancer patients.
While radiation is required by 70
“This will be a breakthrough ‘first-in-class’ IVD test in the field of radiation therapy and one of the first cfDNA tests to be supported by the NCI for real-time detection of normal tissue responses to radiation,” commented Aiguo Zhang, Ph.D., Founder and CEO of DiaCarta, Inc. “We are therefore delighted to have been awarded this contract following successful completion of the $300,000 SBIR Phase I contract in June of this year.”
DiaCarta’s RadTox™ cfDNA Test, a platform diagnostic that monitors circulating cell-free DNA (cfDNA) in patient plasma during radiation therapy, runs on either luminometers or bead-based instrumentation found in many clinical reference laboratories and testing
DiaCarta has been invited to present RadTox™ cfDNA Test at the BIO Investor Forum in San Francisco on October 17-18, 2018, as part of the company’s commitment to a partnering and co-development strategy for the program.
“We are fulfilling an unmet medical need in cancer radiation therapy by enabling the direct monitoring of side effect severity and
Super branched DNA (SuperbDNA™) hybridization technology is a widely used signal amplification clinical platform to quantitatively detect specific nucleic acid sequences directly from the source without the need for DNA/RNA purification or RT-PCR. With a wide dynamic range, bDNA is sensitive enough to reliably detect very few target molecules using DiaCarta’s kits and reagents formatted on a luminometer or bead-based platform. DiaCarta’s SuperbDNA™ technology offers sensitivity for detection of over 4,000 target genes.
DiaCarta, a translational genomics and personalized diagnostics company based in Richmond, California, was established in 2011 to provide highly sensitive and advanced technologies that will improve the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. DiaCarta offers a range of testing services, from single-gene QClamp® qPCR tests to its OptiSeq™ XNA-NGS panels. The company is well positioned as a leader in the new ‘liquid biopsy’ IVD (in vitro diagnostic) field with high-precision detection of cfDNA. DiaCarta is ISO13485 certified and manufactures IVD kits under
DiaCarta announced that CIO Bulletin has named it among the 30 Fastest Growing Companies of 2018. The positioning is based on DiaCarta’s revenue growth, financial status, openness to innovation, global collaboration and partnership, flagship products launching, regulatory progress and ability to forecast future business and technology trends.
DiaCarta announced that it is launching a new suite of CE-IVD marked highly sensitive hydrolysis probe (TaqMan-qPCR) based QClamp® assays for detection of common cancer mutations in genes, such as KRAS, NRAS, BRAF, EGFR, PIK3CA and JAK2, using tissue biopsy (FFPE) and liquid biopsy (cfDNA) samples.
DiaCarta has been recognized as one of the Top 10 In-Vitro Diagnostic Technology Solution Providers 2018 by Med Tech Outlook Magazine. The positioning is based on an evaluation of DiaCarta’s specialty in genomic testing for biomarkers, personalized diagnostics and clinical sample testing service provided in their CLIA-certified lab.
DiaCarta today announced that it has signed a distribution agreement with Arrow Diagnostics. Under the agreement, Arrow Diagnostics becomes sole distributor of ColoScape™ a multigene biomarker TaqMan qPCR in vitro diagnostic (CE-IVD) test in Italy, San Marino & Vatican City.
CIO Applications has chosen DiaCarta as one of the Top 25 Life Sciences Technology Vendors 2018. The positioning is based on an evaluation of DiaCarta’s specialty in personalized diagnostics, translational genomics and clinical sample testing services provided in both US and China.